HomeCompareCNPOF vs JNJ

CNPOF vs JNJ: Dividend Comparison 2026

CNPOF yields 2500.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CNPOF wins by $80609755877.34M in total portfolio value
10 years
CNPOF
CNPOF
● Live price
2500.00%
Share price
$0.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80609755877.37M
Annual income
$74,729,580,081,858,750.00
Full CNPOF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — CNPOF vs JNJ

📍 CNPOF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCNPOFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CNPOF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CNPOF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CNPOF
Annual income on $10K today (after 15% tax)
$212,500.00/yr
After 10yr DRIP, annual income (after tax)
$63,520,143,069,579,940.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, CNPOF beats the other by $63,520,143,069,575,950.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CNPOF + JNJ for your $10,000?

CNPOF: 50%JNJ: 50%
100% JNJ50/50100% CNPOF
Portfolio after 10yr
$40304877938.70M
Annual income
$37,364,790,040,931,720.00/yr
Blended yield
92.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CNPOF
No analyst data
Altman Z
-2.5
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CNPOF buys
0
JNJ buys
0
No recent congressional trades found for CNPOF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCNPOFJNJ
Forward yield2500.00%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$80609755877.37M$30.3K
Annual income after 10y$74,729,580,081,858,750.00$4,689.40
Total dividends collected$80198875900.38M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CNPOF vs JNJ ($10,000, DRIP)

YearCNPOF PortfolioCNPOF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$260,700$250,000.00$10,592$272.30+$250.1KCNPOF
2$6,370,070$6,091,121.50$11,289$357.73+$6.36MCNPOF
3$145,912,632$139,096,656.81$12,123$472.89+$145.90MCNPOF
4$3,133,830,814$2,977,704,297.75$13,141$629.86+$3133.82MCNPOF
5$63,122,812,060$59,769,613,088.96$14,408$846.81+$63122.80MCNPOF
6$1,192,683,724,131$1,125,142,315,226.76$16,021$1,151.60+$1192683.71MCNPOF
7$21,144,559,711,004$19,868,388,126,183.19$18,122$1,588.22+$21144559.69MCNPOF
8$351,818,906,448,043$329,194,227,557,269.44$20,930$2,228.20+$351818906.43MCNPOF
9$5,495,491,397,671,320$5,119,045,167,771,913.00$24,792$3,191.91+$5495491397.65MCNPOF
10$80,609,755,877,367,070$74,729,580,081,858,750.00$30,274$4,689.40+$80609755877.34MCNPOF

CNPOF vs JNJ: Complete Analysis 2026

CNPOFStock

RIV Capital Inc., formerly known as Canopy Rivers Inc., is a venture capital firm. The firm is a stage agnostic, with seed to sale, although it prefers to invest in series A to C rounds. It prefers to make investments in cannabis sector with focus on burgeoning marijuana companies and sectors like agriculture and food sciences, production, processing, pharmaceuticals and biotechnology, software and data, hardware, consumer products and accessories, wellness products, retail and distribution, and media and content. The firm also focuses on beverages, capsules and concentrates, edibles, dry flower / pre-rolls, vaporizers and hardware, pet products, and topicals. In agriculture and food sciences firm focuses in invest plant science, soil science, food science, animal science and environmental science. In production firm focuses in Indoor cultivation, greenhouse cultivation, outdoor cultivation, nursery cultivation and fermentation. In processing firm focuses in harvesting, extraction and purification, packaging, food and beverage processing and laboratory testing services. In pharmaceuticals and biotechnology firm focuses in pharmaceutical discovery and development, delivery method (ex: pill, soft gel, tincture), biosynthetic derived cannabinoids and other molecules, medical devices (ex: inhalers) and lab equipment. In consumer products and accessories firm focuses in edibles, beverages, inhalable, cosmetics and cannabis consumption accessories. In retail and distribution firm focuses in licensed brick and mortar retailers, pharmacies, online consumer marketplaces, delivery services, and others. The firm invests in opportunities globally. The firm prefers to invest in check sizes have ranged from CA$1 million ($0.71 million) to $40 million ($28.45 million), but more typical investment range is between CA$5 million ($3.6 million) to CA$10 million ($7.1 million). The firm is focused on making minority stake investments. Firm employ diverse investment structures including debt, preferred and common equity, and production-linked royalties. RIV Capital Inc. was founded on 2017 and is based in Toronto, Canada.

Full CNPOF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this CNPOF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CNPOF vs SCHDCNPOF vs JEPICNPOF vs OCNPOF vs KOCNPOF vs MAINCNPOF vs ABBVCNPOF vs MRKCNPOF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.